TGRX-678
Phase 1Small molecule
TGRX-678 is one of 55 small molecule programs targeting Chronic Myelogenous Leukemia. It is currently in Phase 1.
1
Indications
6
Total Trials
4
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
120 competitors in Chronic Myelogenous Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Idamycin
PfizerPhase 3
Leukine
SanofiPhase 3
Scemblix
NovartisPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Busulfex
Akero TherapeuticsPhase 3
Droxia
TTheravia
Phase 3
Vepesid
AAvyxa
Phase 3
PEG-Intron
Merck & Co.Phase 3
Gleevec
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Myelogenous Leukemia4 trials
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TGRX-678. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SShenzhen TargetRx Co., Ltd.